Feil Family Brain & Mind Research Institute

You are here

Plasma lipocalin-2 levels in the preclinical stage of Alzheimer's disease.

TitlePlasma lipocalin-2 levels in the preclinical stage of Alzheimer's disease.
Publication TypeJournal Article
Year of Publication2019
AuthorsEruysal E, Ravdin L, Kamel H, Iadecola C, Ishii M
JournalAlzheimers Dement (Amst)
Volume11
Pagination646-653
Date Published2019 Dec
ISSN2352-8729
Abstract

Introduction: Lipocalin-2 is an acute-phase protein with pleotropic functions that has been implicated in several diseases including Alzheimer's disease (AD). However, it is unknown if circulating lipocalin-2 levels are altered in the preclinical stage of AD, where AD pathology has accumulated but cognition remains relatively intact.

Methods: In this cross-sectional study, we used an immunoassay to measure plasma lipocalin-2 levels in cognitively normal (Clinical Dementia Rating 0) elderly individuals. 38 of 156 subjects were classified as preclinical AD by cerebrospinal fluid criteria.

Results: Plasma lipocalin-2 levels were higher in preclinical AD compared with control subjects and associated with cerebrospinal fluid amyloid-beta levels but not cerebrospinal fluid tau or phosphorylated-tau levels. Exploratory analyses revealed that plasma lipocalin-2 was associated with executive function but not episodic memory.

Discussion: Collectively, these results raise the possibility that circulating lipocalin-2 is involved early in AD pathogenesis and may represent an early blood biomarker of amyloid-beta pathology.

DOI10.1016/j.dadm.2019.07.004
Alternate JournalAlzheimers Dement (Amst)
PubMed ID31517027
PubMed Central IDPMC6733778
Grant ListR01 NS037853 / NS / NINDS NIH HHS / United States
K23 NS082367 / NS / NINDS NIH HHS / United States
K08 AG051179 / AG / NIA NIH HHS / United States
P01 AG003991 / AG / NIA NIH HHS / United States
P50 AG005681 / AG / NIA NIH HHS / United States
UL1 TR002384 / TR / NCATS NIH HHS / United States
P01 AG026276 / AG / NIA NIH HHS / United States